Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer

2018385 citationsJournal Article

Authors

Tomoki Ebata · Nagoya University

Satoshi Hirano · Hokkaido University

Masaru Konishi · National Cancer Centre Japan

Katsuhiko Uesaka · Shizuoka Cancer Center

Y. Tsuchiya · Niigata Cancer Center Hospital

Masayuki Ohtsuka · Chiba University

Yuji Kaneoka ·

Abstract

The survival probability in patients with resected bile duct cancer was not significantly different between the gemcitabine adjuvant chemotherapy group and the observation group. Registration number: UMIN 000000820 (http://www.umin.ac.jp/).

Topics & Keywords

Cholangiocarcinoma and Gallbladder Cancer Studies Gallbladder and Bile Duct Disorders Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British journal of surgery

Volume 105, Issue 3, pp. 192-202

DOI: 10.1002/bjs.10776

Field-Weighted Citation Impact: 36.70